[Principles underlying the use of antituberculosis medication in children (author's transl)].
The authors review the principles underlying antituberculosis therapy in children. Basing their comment on the published literature, they analyze the properties, pharmacology, toxicity, and side-effects of each medication, and define their dosage and modes of administration.
D000995:Antitubercular Agents / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D003523:Cycloserine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000627:therapeutic use; D005000:Ethionamide / Q000627:therapeutic use; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D011515:Prothionamide / Q000627:therapeutic use; D011718:Pyrazinamide / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D012294:Rifamycins / Q000627:therapeutic use; D013307:Streptomycin / Q000627:therapeutic use; D014390:Tuberculosis, Meningeal / Q000188:drug therapy; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000995:Antitubercular Agents; D012294:Rifamycins; D011718:Pyrazinamide; D011515:Prothionamide; D004977:Ethambutol; D003523:Cycloserine; D005000:Ethionamide; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin
Principes d'emploi des médicaments antituberculeux chez l'enfant.